AR106645A1 - THERAPEUTIC COMPOSITIONS FOR THE TREATMENT OF HUMAN IMMUNODEFICIENCY VIRUS - Google Patents
THERAPEUTIC COMPOSITIONS FOR THE TREATMENT OF HUMAN IMMUNODEFICIENCY VIRUSInfo
- Publication number
- AR106645A1 AR106645A1 ARP160103426A ARP160103426A AR106645A1 AR 106645 A1 AR106645 A1 AR 106645A1 AR P160103426 A ARP160103426 A AR P160103426A AR P160103426 A ARP160103426 A AR P160103426A AR 106645 A1 AR106645 A1 AR 106645A1
- Authority
- AR
- Argentina
- Prior art keywords
- pharmaceutically acceptable
- acceptable salt
- treatment
- immunodeficiency virus
- human immunodeficiency
- Prior art date
Links
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Forma de dosificación oral sólida, que comprende un compuesto de fórmula (1) o una sal farmacéuticamente aceptable del mismo, tenofovir alafenamida o una sal farmacéuticamente aceptable de la misma, y emtricitabina o una sal farmacéuticamente aceptable de la misma. Reivindicación 31: Un método para producir un comprimido de cualquiera de las reivindicaciones anteriores, en donde el método comprende (a) comprimir el compuesto de fórmula (1) o una sal farmacéuticamente aceptable del mismo como primera capa, y (b) comprimir la tenofovir alafenamida o una sal farmacéuticamente aceptable de la misma y emtricitabina o una sal farmacéuticamente aceptable de la misma como una segunda capa. Reivindicación 34: La primera capa que puede obtenerse mediante el método de la reivindicación 31. Reivindicación 35: La segunda capa que puede obtenerse mediante el método de la reivindicación 31. Reivindicación 36: Un kit que comprende (a) un comprimido que comprende un compuesto de fórmula (1) o una sal farmacéuticamente aceptable del mismo, tenofovir alafenamida o una sal farmacéuticamente aceptable de la misma, y emtricitabina o una sal farmacéuticamente aceptable de la misma, y (b) un desecante.Solid oral dosage form, comprising a compound of formula (1) or a pharmaceutically acceptable salt thereof, tenofovir alafenamide or a pharmaceutically acceptable salt thereof, and emtricitabine or a pharmaceutically acceptable salt thereof. Claim 31: A method of producing a tablet of any of the preceding claims, wherein the method comprises (a) compressing the compound of formula (1) or a pharmaceutically acceptable salt thereof as the first layer, and (b) compressing the tenofovir alafenamide or a pharmaceutically acceptable salt thereof and emtricitabine or a pharmaceutically acceptable salt thereof as a second layer. Claim 34: The first layer that can be obtained by the method of claim 31. Claim 35: The second layer that can be obtained by the method of claim 31. Claim 36: A kit comprising (a) a tablet comprising a compound of formula (1) or a pharmaceutically acceptable salt thereof, tenofovir alafenamide or a pharmaceutically acceptable salt thereof, and emtricitabine or a pharmaceutically acceptable salt thereof, and (b) a desiccant.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562253042P | 2015-11-09 | 2015-11-09 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR106645A1 true AR106645A1 (en) | 2018-02-07 |
Family
ID=61247547
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP160103426A AR106645A1 (en) | 2015-11-09 | 2016-11-10 | THERAPEUTIC COMPOSITIONS FOR THE TREATMENT OF HUMAN IMMUNODEFICIENCY VIRUS |
Country Status (1)
| Country | Link |
|---|---|
| AR (1) | AR106645A1 (en) |
-
2016
- 2016-11-10 AR ARP160103426A patent/AR106645A1/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO2018004776A2 (en) | Therapeutic compositions for the treatment of human immunodeficiency virus | |
| CY1120939T1 (en) | COMBINATION OF REGORAFENIB AND ACETYLSALYLIC ACID FOR THE TREATMENT OF COLON CANCER | |
| CO2017013293A2 (en) | Pharmaceutical formulations comprising tenofovir and emtricitabine | |
| ECSP16084317A (en) | PHARMACEUTICAL FORMULATIONS, PREPARATION PROCESSES AND METHODS OF USE | |
| EA202090098A1 (en) | PHARMACEUTICAL COMPOSITIONS OF THERAPEUTICALLY ACTIVE COMPOUNDS | |
| IL285899A (en) | Pharmaceutical dosage form for application to mucous membranes and methods for producing same | |
| EA201692043A1 (en) | DOSAGE FORM IMMUNODEPRESSANT | |
| PH12016502243A1 (en) | Pharmaceutical compositions for treating infectious diseases | |
| WO2015179823A8 (en) | Lung localized inhibitors of alpha(v)beta 6 | |
| EA201792264A1 (en) | METHODS OF TREATING INFLAMMATORY DISEASES | |
| EA201700356A1 (en) | NEW CYCLOPROPANBENZOFURANILPYRIDOPYRAZINDIONS | |
| WO2016015798A9 (en) | Orodispersible film composition comprising enalapril for the treatment of hypertension in a pediatric population | |
| MX2018014129A (en) | Pharmaceutical composition comprising eteplirsen. | |
| BR112018006206A2 (en) | composition, use of a combination, pharmaceutical fixed dosage form, fixed dosage combination, packaging, and use of a fixed dose combination | |
| EA201890929A1 (en) | LOW DOSES OF DIPYRIDAMOL COMPOSITIONS FOR ORAL ADMINISTRATION AND THEIR USE | |
| AR110374A1 (en) | DOSED FORMS OF MODIFIED GASTRORETENTIVE RELEASE FOR OPROZOMIB AND PROCESS FOR MANUFACTURING | |
| AR106645A1 (en) | THERAPEUTIC COMPOSITIONS FOR THE TREATMENT OF HUMAN IMMUNODEFICIENCY VIRUS | |
| MX2018006631A (en) | Compound for use in the prevention and treatment of neurodegenerative diseases. | |
| ECSP17008187A (en) | PHARMACEUTICAL DOSAGE FORMS | |
| TW201613600A (en) | Piperazinyl derivative reduces HFD-induced accumulation of fat in the liver, therapeutically | |
| CU20180036A7 (en) | THERAPEUTIC COMPOSITIONS FOR THE TREATMENT OF HUMAN IMMUNODEFICIENCY VIRUS | |
| EA201992754A1 (en) | PHARMACEUTICAL COMPOSITIONS | |
| TR201713325A2 (en) | PRODUCTION METHOD FOR FORMULATIONS CONTAINING RIVAROXABAN | |
| TR201713326A2 (en) | Production Method for Formulations Containing Rivaroxaban | |
| EA201892675A1 (en) | PHARMACEUTICAL COMPOSITION CONTAINING ETHEPLIRSEN |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |